Stockreport

CARVYKTI® ? (ciltacabtagene autoleucel; cilta-cel) is the first cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early ...

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF Data featured in a late-breaking oral presentation at the 2024 International Myeloma Society Annual Meeting BEERSE, BELGIUM , Sept. 27, 2024 (GLOBE NEWSWIRE) -- Janss [Read more]